A Phase 2 interventional study of Cabozantinib in Astrocytic Tumors, sponsored by Exelixis. Terminated at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by Exelixis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.
Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 787th largest by enrollment of the 1,155 interventional ones that give a count, is one of 57 that started in 2010, is one of 396 in phase 2, and was the 416th registered.
2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:
Macarena De La Fuente, MD · Sites in United States
Ages 18+
Alpheus Medical, Inc. · Sites in United States
Ages 18–80
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
City of Hope Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
Inova Health Care Services · Sites in United States
Ages 18–98
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,302 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 671 · Phase 2 592 · Phase 3 55 · Phase 4 4
First in 1979; this study’s year is marked. 57 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 33 across the 1,155 interventional studies, 60 across the 79 observational. Of the 882 that completed or were terminated, 344 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
321 of 1,302 have an industry lead sponsor. The 10 most frequent:
Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Exelixis has 3 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
105 of the studies in Glioblastoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT03743662Memorial Sloan Kettering Cancer CenterNivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | 2026-11 |
| NCT04574856University of Michigan Rogel Cancer CenterMultiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | 2026-11-19 |
| NCT02704858Neonc Technologies, Inc.Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | 2026-11-30 |
| NCT05781321Mayo ClinicShort Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study | 2026-11-30 |
Add all 105 to your calendar (.ics) → With an account.
Among the 1,302 studies in Glioblastoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was conducted in subjects with grade IV astrocytic tumors (a type of cancer that can occur in the brain or spinal cord) in first or second relapse.
The goal of this clinical trial is to learn if the drug cabozantinib works for people with astrocytic tumors. It also was designed to learn about the safety of cabozantinib. The main questions are:
Participants were assigned to one of the four treatment groups:
Arm 1. Take cabozantinib at a dose of 25 mg once every day (po QD) continuously until progression.
Arm 2. Take cabozantinib at a dose of 75 mg once every day continuously until progression.
Arm 3. Take cabozantinib at a dose of 125 mg once every day for 2 weeks, followed by 50 mg every day (po QD) for the remainder of the treatment period;
Arm 4. Take cabozantinib at a dose of 125 mg once every day for 2 weeks, followed by 1 week off. For the remainder of the treatment period, patients received cabozantinib at a dose of 125 mg once every day for three weeks followed by one week of rest.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Starting dose of 25 mg, once a day by mouth (po QD) continuously
Drug: Cabozantinib
Starting dose of 75 mg, po QD, continuously
Drug: Cabozantinib
Starting dose of 125 mg, po QD for 2 weeks, followed by 50 mg, po QD for the remainder of the treatment period.
Drug: Cabozantinib
Initially, the starting dose was 125 mg, po QD for 2 weeks, followed by 1 week off. For the remainder of the treatment, the dosing frequency was reduced to 125 mg, po QD every 3 weeks, followed by 1 week of rest for the remainder of the treatment period.
Drug: Cabozantinib
Also known as: XL-184
Randomized Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An AE was defined as any event with an onset date on or after the date of first dose of study drug, or any ongoing event on the date of first dose that worsened in severity after the date of first dose. TEAEs were defined as AEs that started on or after the first administration of study drug up to the date of last dose plus 30 days. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.
Time frame: Up to 13 months
Expansion Phase: Objective Response Rate (ORR)
ORR was defined as the number of participants for whom the best overall response at the time of data cutoff is confirmed complete response (CR) or confirmed partial response (PR) as assessed per modified Response Assessment in Neuro-Oncology (RANO) criteria. CR = Disappearance of all enhancing target lesion(s) and no glucocorticoids (other than a physiologic replacement dose of a maximum of 1.2 mg dexamethasone equivalent dose per day) taken for the 5 days immediately preceding the date of the current magnetic resonance imaging (MRI). PR = ≥50% decrease in the sum of the products of perpendicular diameters of all target enhancing lesions on the current MRI scan compared to the baseline MRI scan and glucocorticoids stable or decreased. The sponsor terminated the study early due to business reasons before entering the expansion phase. As such, no data were collected for efficacy analyses.
Time frame: Up to 13 months
Expansion Phase: Progression Free Survival at 6 Months as Per Independent Radiology Facility
Progression-free survival at 6 months (PFS6) was defined as the proportion of participants alive and progression-free 182 days after Study Day 1. The sponsor terminated the study early due to business reasons before entering the expansion phase. As such, no data were collected for efficacy analyses.
Time frame: Month 6
The enrollment in this study was terminated early for business development reasons.
| Milestone | Arm 1 - Cabozantinib, 25 mg | Arm 2 - Cabozantinib, 75 mg | Arm 3 - Cabozantinib, 125 mg | Arm 4 - Cabozantinib, 125 mg, QD for 2 Weeks, Followed by 1 Week Off |
|---|---|---|---|---|
| Started | 5 | 4 | 6 | 4 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 5 | 4 | 6 | 4 |
| Withdrew: Business decision | 5 | 4 | 6 | 4 |
An AE was defined as any event with an onset date on or after the date of first dose of study drug, or any ongoing event on the date of first dose that worsened in severity after the date of first dose. TEAEs were defined as AEs that started on or after the first administration of study drug up to the date of last dose plus 30 days. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.
| Participants | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| Randomized Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 5 | 3 | 6 | 4 |
ORR was defined as the number of participants for whom the best overall response at the time of data cutoff is confirmed complete response (CR) or confirmed partial response (PR) as assessed per modified Response Assessment in Neuro-Oncology (RANO) criteria. CR = Disappearance of all enhancing target lesion(s) and no glucocorticoids (other than a physiologic replacement dose of a maximum of 1.2 mg dexamethasone equivalent dose per day) taken for the 5 days immediately preceding the date of the current magnetic resonance imaging (MRI). PR = ≥50% decrease in the sum of the products of perpendicular diameters of all target enhancing lesions on the current MRI scan compared to the baseline MRI scan and glucocorticoids stable or decreased. The sponsor terminated the study early due to business reasons before entering the expansion phase. As such, no data were collected for efficacy analyses.
No measurements were reported for this outcome.
Progression-free survival at 6 months (PFS6) was defined as the proportion of participants alive and progression-free 182 days after Study Day 1. The sponsor terminated the study early due to business reasons before entering the expansion phase. As such, no data were collected for efficacy analyses.
No measurements were reported for this outcome.
Collected over Up to 13 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Arm 2 | 0/4 (0%) | 1/4 (25%) | 3/4 (75%) |
| Arm 3 | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Arm 4 | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Event | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| Intracranial Tumour HaemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/5 | 0/4 | 0/6 | 1/4 |
| Mental Status ChangesPsychiatric disorders | 0/5 | 1/4 | 0/6 | 0/4 |
| NauseaGastrointestinal disorders | 0/5 | 1/4 | 0/6 | 0/4 |
| VomitingGastrointestinal disorders | 0/5 | 1/4 | 0/6 | 0/4 |
| DehydrationMetabolism and nutrition disorders | 0/5 | 1/4 | 0/6 | 0/4 |
| MigraineNervous system disorders | 1/5 | 0/4 | 0/6 | 0/4 |
| ConvulsionNervous system disorders | 1/5 | 0/4 | 0/6 | 0/4 |
| Basal Ganglia InfarctionNervous system disorders | 0/5 | 0/4 | 1/6 | 0/4 |
| Clostridial InfectionInfections and infestations | 0/5 | 0/4 | 1/6 | 0/4 |
| Event | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| FatigueGeneral disorders | 3/5 | 3/4 | 5/6 | 2/4 |
| NauseaGastrointestinal disorders | 3/5 | 3/4 | 3/6 | 2/4 |
| DiarrhoeaGastrointestinal disorders | 1/5 | 2/4 | 3/6 | 2/4 |
| Tinea pedisInfections and infestations | 0/5 | 0/4 | 0/6 | 2/4 |
| Blood thyroid stimulating hormone increasedInvestigations | 0/5 | 2/4 | 1/6 | 1/4 |
| HeadacheNervous system disorders | 2/5 | 0/4 | 3/6 | 2/4 |
| DepressionPsychiatric disorders | 0/5 | 2/4 | 2/6 | 1/4 |
| HypertensionVascular disorders | 1/5 | 1/4 | 1/6 | 2/4 |
| Lipase increasedInvestigations | 2/5 | 0/4 | 0/6 | 1/4 |
| FlatulenceGastrointestinal disorders | 0/5 | 0/4 | 2/6 | 0/4 |
| Age, Customized(Participants) | Arm 1 - Cabozantinib, 25 mg | Arm 2 - Cabozantinib, 75 mg | Arm 3 - Cabozantinib, 125 mg, Followed by 50 mg, po QD for the Remainder of the Treatment Period. | Arm 4 - Cabozantinib, 125 mg, QD for 2 Weeks, Followed by 1 Week Off | Total |
|---|---|---|---|---|---|
| 18 - <25 years | 0 | 0 | 0 | 0 | 0 |
| 25 - <45 years | 1 | 0 | 3 | 0 | 4 |
| 45 - <65 years | 4 | 4 | 1 | 4 | 13 |
| 65 years and Over | 0 | 0 | 2 | 0 | 2 |
| Sex: Female, Male(Participants) | Arm 1 - Cabozantinib, 25 mg | Arm 2 - Cabozantinib, 75 mg | Arm 3 - Cabozantinib, 125 mg, Followed by 50 mg, po QD for the Remainder of the Treatment Period. | Arm 4 - Cabozantinib, 125 mg, QD for 2 Weeks, Followed by 1 Week Off | Total |
|---|---|---|---|---|---|
| Female | 4 | 1 | 1 | 3 | 9 |
| Male | 1 | 3 | 5 | 1 | 10 |
| Race (NIH/OMB)(Participants) | Arm 1 - Cabozantinib, 25 mg | Arm 2 - Cabozantinib, 75 mg | Arm 3 - Cabozantinib, 125 mg, Followed by 50 mg, po QD for the Remainder of the Treatment Period. | Arm 4 - Cabozantinib, 125 mg, QD for 2 Weeks, Followed by 1 Week Off | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 5 | 4 | 5 | 4 | 18 |
| More than one race | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
The record gives a start of Apr 2010, a primary completion of May 2011 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2026, 14 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabozantinib